Articles published in Journal of Stem Cell Research & Therapy have been cited by esteemed scholars and scientists all around the world. Journal of Stem Cell Research & Therapy has got h-index 33, which means every article in Journal of Stem Cell Research & Therapy has got 33 average citations.
Following are the list of articles that have cited the articles published in Journal of Stem Cell Research & Therapy.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
22 | 58 | 59 | 65 | 23 | 13 | 36 | 34 | 49 | 63 | 101 | 62 | 44 | 26 |
Research, Review articles and Editorials |
2 | 4 | 1 | 2 | 12 | 12 | 29 | 28 | 44 | 56 | 80 | 48 | 12 | 19 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
20 | 54 | 58 | 63 | 11 | 1 | 7 | 6 | 5 | 7 | 21 | 14 | 32 | 6 |
Conference proceedings |
0 | 40 | 12 | 37 | 0 | 0 | 145 | 138 | 95 | 63 | 154 | 72 | 54 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
522 | 678 | 761 | 838 | 697 | 626 | 613 | 599 | 538 | 478 | 262 | 142 | 31 | 69 |
Journal total citations count | 6793 |
Journal impact factor | 1.64 |
Journal 5 years impact factor | 1.70 |
Journal cite score | 11.56 |
Journal h-index | 33 |
Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial
Engineering precision therapies: lessons and motivations from the clinic
Genome writing: current progress and related applications
Gene therapy for X-linked severe combined immunodeficiency: historical outcomes and current status
Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice
Next generation sequencing in newborn screening in the United Kingdom National Health Service
Advances and highlights in primary immunodeficiencies in 2017
Thymus autonomy as a prelude to leukemia
Gene therapy using haematopoietic stem and progenitor cells
T cell acute lymphoblastic leukemia as a consequence of thymus autonomy
Gene therapy and genome editing for primary immunodeficiency diseases
CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation
From stem cells to functional lymphocytes: cell differentiation and gene therapy implementation for RAG-SCID
Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
Defining B cell tolerance checkpoints and their modulation by immunotherapy
Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich Syndrome
Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Ex-Vivo Gene Editing
CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich's
Self-renewal of double-negative 3 early thymocytes enables thymus autonomy but compromises the ?-selection checkpoint
p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy